Guideline recommendations on the use of dual antiplatelet therapy have been formulated that
ticagrelor 90 mg twice daily plus aspirin in preference to clopidogrel 75mg daily plus
aspirin for ACS patients. Recent study found that ticagrelor 90mg twice a day orally could
significantly reduce the occurrence of clopidogrel resistance and adverse cardiovascular
events. The previous studies have reported that half-dose ticagrelor had the similar
inhibitory effect on platelet aggregation as the standard-dose ticagrelor, which was
significantly stronger than that in the clopidogrel group. One-quarter standard-dose
ticagrelor provided greater degree of platelet inhibition than standard dose clopidogrel in
Chinese patients with stable CAD. But large-scale clinical trials are still needed to confirm
the effects of low-dose ticagrelor on platelet function in Chinese patients with coronary
heart disease.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
First Affiliated Hospital of Harbin Medical University
Collaborators:
Beijing Anzhen Hospital RenJi Hospital Shaanxi Provincial People's Hospital Shengjing Hospital The Central Hospital of Jia Mu Si City The First Affiliated Hospital of Dalian Medical University The First Affiliated Hospital of Kunming Medical College Tianjin Medical University General Hospital Weifang People's Hospital Wuhan Union Hospital, China